Clinical Trial Detail

NCT ID NCT02257424
Title Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma (BAMM)
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Abramson Cancer Center of the University of Pennsylvania
Indications

melanoma

Therapies

Dabrafenib + Hydroxychloroquine + Trametinib

Age Groups: adult senior

Additional content available in CKB BOOST